Before joining Onxeo, Dr. Shefali Agarwal was Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Dr. Agarwal also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA(r) (niraparib) in ovarian cancer. Dr. Agarwal has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. In addition to receiving her medical degree, Dr. Agarwal holds a master’s of public health and a master’s of science in business.
Shefali AGARWAL, MD
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Julien MIARA
Julien Miara is a Principal at Invus. He joined in 2010 as an analyst in the Public Equity group, covering Biotechnology among other sectors.
Since 2018, Julien leads the team in Europe. Previously, he worked in investment banking at BNP Paribas in Paris and Société Générale in New-York, as well as in management consulting. Julien Miara received his Master of Management from EDHEC Business School in Lille (France) in 2009.
At its meeting on September 17, 2020, the Board of Directors of Onxeo co-opted Mr. Julien Miara as a director of the Company. This cooptation was ratified by the Company’s ordinary general meeting of June 10, 2021.
Mr. Julien Miara was appointed as interim CEO of Onxeo on January 3, 2022.
Julien MIARA
DIRECTOR - REPRESENTING INVUS
Bryan GIRAUDO
Bryan Giraudo is both the Chief Operating Officer & Chief Financial Officer of Gossamer Bio, a U.S. listed biopharmaceutical company (Nasdaq: GOSS) focused on developing and commercializing innovative therapeutics in the areas of immunology, inflammation and oncology.
Previously, he served as Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Mr Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Division.
Bryan GIRAUDO
INDEPENDENT DIRECTOR
Nicolas TREBOUTA
Nicolas Trebouta is a Doctor of Medicine.
Co-founder of Chevrillon and Associates in 2000, Nicolas Trebouta has lead several buyouts within this structure including Picard frozen foods, CPI printing or Albingia insurance. Since 2004, he has been investing in biotechnology companies through his company Financière de la Montagne, either directly or through biotech funds. Nicolas Trebouta has been a shareholder of BioAlliance Pharma since 2008.
Financière de la Montagne has been a director since 29 June 2011. Their mandate will expire at the shareholders’ annual general meeting of 2023.
Nicolas TREBOUTA
DIRECTOR - REPRESENTING FINANCIÈRE DE LA MONTAGNE
Danièle GUYOT-CAPARROS
Danièle Guyot-Caparros is a chartered accountant.
Danièle Guyot-Caparros is graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle Guyot-Caparros has been working as a consultant specialized in the life sciences and healthcare areas for 5 years.
Danièle Guyot-Caparros has been a director of Onxeo since 26 June 2013 and Chairperson of the Board of Directors since 22 May 2019. Her mandate will expire at the annual shareholders’ general meeting of 2022.
Danièle GUYOT-CAPARROS
INDEPENDENT DIRECTOR
Jacques MALLET
Jacques Mallet, MD, served as SVP - Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently board member of several listed or private companies in the health technology sector. He brings to Onxeo more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development and Corporate Strategy and a unique insight gained in life sciences both in Europe and the United States as a venture capitalist. Prior to this, Mr Mallet had been responsible for investments at Auriga Partners, a key life sciences specialized private-equity firm in France, and held executive positions in global consulting firms such as Monitor Deloitte and Accenture.
Jacques MALLET
INDEPENDENT DIRECTOR
Robert L. COLEMAN
Robert L. Coleman, MD, is the Chief Scientific Officer of US Oncology Research, one of the U.S. largest networks dedicated to advancing high-quality, evidence-based cancer care and research, with more than 400 clinical studies underway and gathering over 1400 physicians. Prior to joining the US Oncology Network in 2020, Dr Coleman served as executive director of MD Anderson's Cancer Network Research Program. Additionally, he was a professor and also served as the Ann Rife Cox Chair in Gynecology at The University of Texas. Dr Coleman's work has been featured in over 500 publications focusing on the role of novel therapies in ovarian cancer, such as the incorporation of PARP inhibitors in the treatment strategy.
